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Abstract 34 
INTRODUCTION: Ischaemic preconditioning (IPC) may enhance 35 
endurance performance. No previous study has directly compared 36 
distinct IPC protocols for optimal benefit. The aim of this study was 37 
to determine whether a specific IPC protocol (i.e. number of cycles, 38 
amount of muscle tissue, and local vs remote occlusion) elicits 39 
greater performance outcome.  40 
METHODS: Twelve cyclists performed five different IPC protocols 41 
30-min prior to a blinded 375 kJ cycling time trial (TT) in a 42 
laboratory. Responses to traditional IPC (4x5-min legs) were 43 
compared to: i. 8x5-min legs and SHAM (“dose-cycles”), ii. 4x5-44 
min unilateral legs (“dose-tissue”), and iii. 4x5-min arms 45 
(“remote”). RPE and blood lactate were recorded at each 25% TT 46 
completion. Power (watts), heart rate (bpm), and ?̇?O2 (ml.kg.min-1) 47 
were measured continuously throughout TT’s. Magnitude based 48 
inference statistics were employed to compare variable differences 49 
to the minimal practically important difference. 50 
RESULTS: Traditional IPC was associated with a 17 (0, 34) secs 51 
faster TT time compared to SHAM. Applying more “dose-cycles” 52 
(8x5-min) had no impact on performance. Traditional IPC was 53 
associated with “likely trivial” higher blood lactate and “possibly 54 
beneficial” lower ?̇?O2 responses vs. SHAM. Unilateral IPC was 55 
associated with 18 (-11, 48) secs slower performance compared to 56 
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bilateral (“dose-tissue”). TT times following remote and local IPC 57 
were not different [0 (-16, 16) secs]. 58 
CONCLUSION: The traditional 4x5-min (local or remote) IPC 59 
stimulus resulted in the fastest TT time compared to SHAM, there 60 
was no benefit of applying a greater number of cycles or employing 61 
unilateral IPC.  62 
Key words: Exercise, Occlusion, Ischaemia, Time Trial, Endurance 63 
 64 
Introduction 65 
Ischaemic preconditioning (IPC) refers to the phenomenon whereby 66 
3-4 brief periods of ischaemia, followed by tissue reperfusion, 67 
confers subsequent tissue protection against ischaemic insult 1. IPC 68 
can be applied remotely by placing a blood pressure cuff around a 69 
limb and inflating to supra-systolic pressure. Studies have generally 70 
employed remote IPC in clinical populations relating to cardio-71 
protection, but there is accumulating evidence that remote IPC can 72 
impact on other organs (e.g. skeletal muscle), and vascular beds to 73 
facilitate increased blood flow 2,3. These finding have resulted in the 74 
application of IPC to determine its efficacy as a potential pre-75 
exercise priming strategy. 76 
The first study to investigate IPC in a human exercise model 77 
demonstrated a 3% improvement in maximal oxygen uptake (?̇?O2) 78 
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following a 3x5-min bilateral leg cuff inflation (220 mmHg) 79 
protocol 4. A “traditional” IPC protocol consists of 3x5- or 4x5-min 80 
bouts of occlusion. More recently, studies have separately employed 81 
alternative IPC protocols (altering the number of IPC cycles, tissue 82 
occlusion area, and cuff location), with the aim of observing greater 83 
performance and clinical outcomes. There are now (pre)clinical 84 
studies providing evidence for a “dose”-dependency, where 85 
repeated daily IPC improves (cerebro)vascular function and clinical 86 
outcomes 5,6. Nonetheless, a potential ‘hyper-conditioning’ effect 87 
from excessive cycles of IPC cannot be excluded 7. Corroborating 88 
the “dose”-hypothesis, recent work suggests that bilateral, but not 89 
unilateral cuff inflation leads to improved exercise performance 8. 90 
Finally, most studies to date have opted for cuff positioning directly 91 
on the exercising limb 9, but cuff placement on remote, non-92 
exercising limbs has also been performed 10 to examine a systemic 93 
effect. In line with clinical observations in the protection of organs 94 
against ischaemic injury, local or remote application of IPC may 95 
induce comparable benefits 2,11. 96 
Recently, a systematic review and meta-analysis reported a small 97 
beneficial effect of IPC on exercise performance, with the largest 98 
effect observed in aerobic-based tasks 12. Despite the effect sizes 99 
being small, the potential benefits of IPC may translate to 100 
meaningful differences in competitive (time trial-based) events.  101 
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Interestingly, no study has directly compared the capacity of distinct 102 
IPC protocols with the aim of electing greater performance 103 
improvement. Therefore, the aim of this study was to examine 104 
whether the (i) number IPC cycles (i.e. “dose-cycles”), (ii) the 105 
amount of muscle mass occluded (“dose-tissue”), and (iii) the 106 
application of IPC to either local or remote limbs (“remote”) offers 107 
greater improvements to endurance cycling performance. 108 
Methods 109 
Participants 110 
Twelve trained cyclists (mean±SD: age, 36±7 years; body mass, 111 
78±4 kg; height, 179±6 cm; ?̇?O2max, 59±4 ml.kg-1.min-1) were 112 
recruited. Participants were undertaking regular weekly training 113 
sessions (5±3 sessions) and mean weekly training volume was 8±4 114 
hours. The mean training experience was 9±8 years. Following 115 
verbal and written explanation of procedures, all participants 116 
provided written informed consent. Physical Activity Readiness 117 
Questionnaires were administered to ensure no participant had any 118 
health implications that would prevent participation. All individuals 119 
refrained from exercise and alcohol consumption 24 hours, and 120 
consumption of caffeine at least 6 hours, respectively prior to all 121 
laboratory visits. The study was approved by the local Ethics 122 
Committee. 123 
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Research Design 124 
The study was divided into three comparisons as illustrated in figure 125 
1. All participants completed a maximal graded cycling test and at 126 
least two familiarization TT. Prior to commencement of the five 127 
experimental cycling TT’s, an IPC protocol was administered. A 128 
traditional (4x5-min) IPC protocol was compared firstly to SHAM, 129 
and a larger (8x5-min) IPC protocol for the “dose-cycles” 130 
comparison. Whilst it was compared to a unilateral (4x5-min) IPC 131 
protocol for the “dose-tissue” comparison. Finally, to assess the 132 
importance of cuff placement, a 4x5-min bilateral IPC protocol was 133 
applied to the non-exercising upper limb for the “remote” 134 
comparison.  135 
Experimental Protocol 136 
In a randomized, counterbalanced, crossover study, participants 137 
reported to the laboratory at the same time of day on five separate 138 
occasions, at least 4 days apart, receiving a different pre-exercise 139 
IPC protocol during each visit. Following each IPC protocol, a 20-140 
minute rest period, and a standardized warm up was performed 141 
before the completion of a 375 kilojoule (kJ) cycling time trial (TT). 142 
The TT was intended to simulate the demands of a 16.1 km TT. 143 
During each TT, heart rate and oxygen uptake (?̇?O2) was measured 144 
continuously, whilst blood lactate and rate of perceived of exertion 145 
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(RPE) was recorded at every 25% completed of the TT kilojoule 146 
target. 147 
Measurements 148 
Assessment of maximal oxygen uptake (?̇?O2max). At least 7 days prior 149 
to the first familiarisation trial, participants performed a continuous 150 
incremental step test on an electromagnetically braked cycle 151 
ergometer (SRM, Julich, Germany) to determine lactate threshold 152 
and ̇?̇?O2max. The incremental protocol consisted of 3-minute cycling 153 
stages, commencing at 95 watts (W) and increasing 35W until 154 
volitional exhaustion occurred. Blood lactate concentration was 155 
obtained via finger prick capillary sampling using a safety lancet 156 
(BD Microtainer® Contact-Activated Lancet) after administration 157 
of a disposable sterile isoprophyl alcohol swab (China MEHECO 158 
Co., Ltd.). Blood was collected into a sodium-heparinized blood gas 159 
capillary tube (Marienfeld Superior, Germany) and immediately 160 
analysed in duplicate (ABL90 FLEX, Radiometer Medical ApS, 161 
Denmark) during the last 30 seconds of each incremental stage. 162 
Throughout the incremental cycling test, breath-by-breath expired 163 
gases were monitored for oxygen consumption, ventilation and 164 
respiratory exchange ratio (RER) (MasterScreen™ CPX, 165 
Carefusion, Germany) and the highest 30-second average was taken 166 
from 3 consecutive 10-second bins to subsequently 167 
determine ̇?̇?O2max. Heart rate (HR) was also monitored continuously 168 
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(Polar H1, Kempele, Finland). Wmax was calculated from the last 169 
completed workload, plus the fraction of time spent in the final non-170 
completed stage multiplied by the work rate increment 13. 171 
Familiarisation. At least 2 familiarisation trials were undertaken 172 
prior to the first experimental TT to ensure performance was 173 
reliable. Data from familiarisation sessions revealed a mean 174 
coefficient of variation (CoV) of 1.06% which was deemed to be 175 
acceptable for the purpose of this TT study. 176 
IPC protocols. For the IPC and SHAM trials, 13.5 cm wide cuffs 177 
were used. Participants lay in the supine position and cuff inflation 178 
pressure was set at a standardized pressure (220mmHg) in all IPC 179 
conditions with the aim of preventing arterial inflow 14 and 20mmHg 180 
in SHAM (i.e. cuffs were placed but only inflated to 20mmHg) with 181 
the use of an automatic rapid cuff inflator (Hokanson, Washington, 182 
USA). Subsequently, cuffs were deflated for 5 minutes, allowing 183 
reperfusion. This process was repeated four times in all protocols 184 
except for the “dose-cycles” protocol where 8 cycles were used 185 
(Figure 1). For IPC on the leg, the cuff was placed (unilaterally or 186 
bilaterally) on the most proximal portions of the upper thigh (distal 187 
to the inguinal fold). For remote IPC, cuffs were placed on the most 188 
proximal portions of the upper arms. Each participant gave a 189 
“perceived discomfort” rating at four time points (every 25%) 190 
throughout the IPC or SHAM protocols. The discomfort rating was 191 
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established using a Numerical Rating Scale (NRS) ranging from 0 192 
(no discomfort) to 10 (maximum discomfort) and are included for 193 
descriptive purpose (Table 4) 15. 194 
375 kJ TT. After 20 minutes of rest following cessation of 195 
IPC/SHAM, a capillary blood lactate sample was obtained from the 196 
finger and analysed for resting lactate levels (ABL90 FLEX, 197 
Radiometer Medical ApS, Denmark). Participants then completed a 198 
standardized warm up on an electromagnetically braked cycle 199 
ergometer (SRM, Julich, Germany). The warm up lasted 200 
approximately 10 minutes (5-min at 100W, 2-min at 150W, [15-secs 201 
at Wmax, 30-secs at 150W, repeat x3], 45-secs at 150W). Once the 202 
flywheel had completely stopped turning, the SRM clock was reset 203 
to zero and a 375 kJ TT was performed (exactly 35 minutes after 204 
completion of IPC in all trials). Participants were instructed to 205 
produce a maximum effort throughout TT’s, but were blinded to 206 
power output, elapsed time and HR. Breath-by-breath expired gases 207 
and HR were measured continuously, while RPE and blood lactate 208 
measurements were acquired at 25%, 50%, 75% and 100% time 209 
points (all described previously). Participants were notified once 210 
they had completed each quarter of the TT and when they had 30 kJ 211 
of work remaining. No encouragement or feedback was given 212 
throughout any trial.  213 
Statistical Analysis 214 
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The primary outcome variable was TT time and was analyzed using 215 
a repeated measures general linear modelling for “dose-cycles” (3 216 
levels: SHAM, 4x5-min, 8x5-min) and paired t-tests for “dose-217 
tissue” (2 levels: unilateral, bilateral) and ‘remote’ (2 levels: local, 218 
remote). For TT measures, ?̇?O2, power, lactate, HR, and RPE were 219 
analyzed using repeated measures general linear modelling. The 220 
least significant method was employed for pairwise comparisons 16. 221 
Using a magnitude based inferences framework, the mean effect of 222 
each TT comparison for each variable was presented with the 223 
uncertainty of the estimates presented as 90% confidence intervals 224 
(appropriate SI units used for a given variable). The mean difference 225 
between each comparison were evaluated for their practical 226 
significance by pre-specifying the smallest worthwhile change 227 
(SWC) 17. For TT time and power output, the SWC was calculated 228 
using 0.3 x coefficient of variation from the familiarization trials, 229 
equating to 4.5 seconds and 1 watt, respectively 18. The noise to 230 
signal ratio was determined by calculating the typical error (SD of 231 
between-trial differences divided by √2). The typical error for time 232 
and power was 18 seconds and 4 watts, respectively.   For blood 233 
lactate and ?̇?O2 the SWC was calculated using the standardized 234 
mean difference of 0.2 between subject standard deviations (SD) as 235 
they were not measured during the familiarisation trials 19. The 236 
SHAM values were used for this purpose. The mean difference 237 
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between each comparison, together with its uncertainty, the 238 
probability (percent chances) that the true population effect was 239 
beneficial (>SWC), harmful (>SWC with opposite sign), or trivial 240 
(within ± SWC) was calculated 18. Using mechanistic inferences, 241 
qualitative probabilistic terms for benefit were assigned to each 242 
effect using the following scale; <0.5%, most unlikely or almost 243 
certainly not; 0.5 to 5%, very unlikely; 5 to 25%, unlikely or 244 
probably not; 25 to 75%, possibly; 75 to 95%, likely or probably; 95 245 
to 99.5%, very likely; >99.5%, most likely or almost certainly 18. An 246 
unclear effect is possibly beneficial (>25%) with an unacceptable 247 
risk of harm (>0.5%) and an odds ratio for benefit:harm of <66 248 
interpreted from current recommendations; all other effects are 249 
clear. Data that were lower than the typical error (noise > signal) for 250 
TT performance were interpreted as “unclear” and reported with the 251 
confidence limits within the text and in figure 2.  252 
Results 253 
Dose-cycles 254 
TT time: TT time was 17 secs (90% CI: 0, 34 secs; P=0.097) faster 255 
following the traditional IPC protocol compared to SHAM. The 256 
mean change is lower than the noise so is interpreted as “unclear” 257 
with the following confidence limits 89% chance beneficial, 9% 258 
chance trivial and 2% chance harmful (Figure 2b). Increasing the 259 
“dose” by applying more cycles (8x5-min) did not result in a faster 260 
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TT time compared to traditional IPC (4x5-min) [13 secs (-19, 44 261 
secs); P=0.49, (beneficial 67%, trivial 15%, harmful 18%)] Figure 262 
2]. The effect between IPC with 8x5-min cycles and SHAM on 263 
exercise performance was interpreted as “unclear” (beneficial 50%, 264 
trivial 19%, harmful 31%). 265 
?̇?O2: ?̇?O2 was 0.99 ml.kg.min-1 (-1.7, -0.3 ml.kg.min-1) lower 266 
following traditional IPC compared to SHAM, interpreted as 267 
“possibly beneficial” (beneficial 59%, trivial 41%, harmful 0%; 268 
P=0.03). A “likely trivial” difference was evident between 269 
traditional IPC and the 8x5-min protocol [0.51 ml.kg.min-1(-1.2, 0.2 270 
ml.kg.min-1); (beneficial 17%, trivial 83%, harmful 0%)  P=0.25].  271 
Lactate: Blood lactate increased throughout TT performance, with 272 
highest values observed during the 4th quarter (Table 1). Traditional 273 
IPC was associated with a higher mean TT blood lactate compared 274 
to SHAM [0.73 mmol.L-1 (0.1, 1.5 mmol.L-1); P=0.06, “possibly 275 
trivial” (beneficial 42%, trivial 58%, harmful 0%)] and to the 8x5-276 
min protocol [0.9 mmol.L-1 (0.4, 1.9 mmol.L-1); P=0.006, “possibly 277 
beneficial” (beneficial 73%, trivial 27%, harmful 0%)]. 278 
Power / HR / RPE: HR and RPE increased significantly across time 279 
(P<0.05), whilst power was highest during the 1st quarter. No 280 
further differences were evident for power, HR, or RPE between 281 
traditional, SHAM and 8x5-min (all P>0.05; Table 1).  282 
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Dose-tissue 283 
TT Time: Traditional bilateral IPC resulted in an 18 secs (-11, 48 284 
secs, P=0.29; Figure 2) faster TT performance than unilateral IPC. 285 
Nevertheless, this change was interpreted as “unclear” (beneficial 286 
78%, trivial 12%, harmful 10%). 287 
?̇?O2:  The lower resultant ?̇?O2 following traditional IPC compared 288 
to unilateral IPC [0.8 ml.kg.min-1; (-2, 0.4 ml.kg.min-1); (beneficial 289 
45%, trivial 54%, harmful 1%) P=0.26)] was interpreted as 290 
“possibly trivial”. The time-dependent effect (Table 2), was not 291 
different between the 2 trials.  292 
Lactate: Blood lactate increased throughout TT performance, with 293 
highest values during 4th quarter (Table 2). The mean blood lactate 294 
difference of 0.05 mmol.L-1 (-1.3, 1.4 mmol.L-1); (beneficial 11%, 295 
trivial 81%, harmful 9%; P=0.95) between protocols was 296 
interpreted as “unclear”.  297 
Power / HR / RPE: HR and RPE increased significantly across time, 298 
whilst power was highest during the 1st quarter (Table 2) .No further 299 
differences were evident for power, HR, or RPE (Table 2).  300 
Remote  301 
TT time: The comparison of traditional IPC and remote IPC resulted 302 
in a negligible difference in mean TT time [0 secs (-16, 16 secs; 303 
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P=1.0, Figure 2a)]; interpreted as an “unclear” (beneficial 50%, 304 
trivial 0, harmful 50%). 305 
?̇?O2: ?̇?O2 was 1.1 ml.kg.min-1 (-1.9, -0.2 ml.kg.min-1; (beneficial 306 
71%, trivial 29%, harmful 0%) P=0.04) lower following the 307 
traditional protocol compared to remote IPC, interpreted as a 308 
“possibly beneficial” reduction. 309 
Lactate: Blood lactate increased throughout both TT performances, 310 
with highest values observed during 4th quarter (Table 3). A mean 311 
blood lactate difference of 0.2 mmol.L-1 occurred (-1.2, 1.6 mmol.L-312 
1; P=0.8) between both protocols, interpreted as an “unclear” 313 
difference (beneficial 18%, trivial 74%, harmful 8%).  314 
Power / HR / RPE: HR and RPE increased significantly across time, 315 
whilst power was highest during the 1st quarter. No further 316 
differences were evident for power, HR, or RPE between traditional 317 
and remote IPC (Table 3).  318 
Discussion 319 
The aim of this study was to determine the impact of different IPC 320 
protocols on cycling endurance performance. Specifically we 321 
explored, for the first time, whether the “dose” of IPC, reflected by 322 
either the number of cycles, or the amount of muscle tissue 323 
occluded, affects endurance cycling TT performance. We provide 324 
evidence that the traditional (4x5-min) occlusion/reperfusion cycles 325 
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resulted in the fastest TT times. Our data may support application of 326 
a traditional IPC “dose” of cycles, since increasing the “dose” by 327 
applying more cycles and reducing the “dose” by applying unilateral 328 
IPC, resulted in no further benefit to endurance performance. 329 
Furthermore, our study provides evidence that the same magnitude 330 
of change in TT time (17 seconds) occurs when exposed to either 331 
local or remote application of IPC. 332 
Ischaemic preconditioning, applied using the traditional (4x5-min) 333 
inflation/reperfusion cycles 9,20–24, mediated an effect that was an 334 
unclear performance improvement in a 375 kJ cycling TT based on 335 
a the signal to noise ratio. The improvement of 17 seconds following 336 
traditional IPC vs SHAM is marginally below the calculated error 337 
and the confidence intervals do not cross zero therefore we are 338 
confident that a directional change is present in favor of a 339 
worthwhile performance improvement. Furthermore, our 340 
observation of a 1.4% performance change is largely in line with 341 
previous reports examining the impact of traditional IPC on 342 
endurance-type exercise tasks 12, but it is important to emphasise 343 
that we included a trained population (natural coefficient of 344 
variation of 1.1%); something not commonly observed to date in 345 
time-trial based performance tasks, with the exception of 346 
competitive swimmers 20,25,26. The research evidence suggests IPC 347 
can improve exercise capacity in recreationally trained participants 348 
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4, but one  recent study demonstrated that in highly trained athletes, 349 
IPC provided little benefit in improving exercise capacity 27. 350 
Whether a higher aerobic capacity blunts the ergogenic effect of IPC 351 
on exercise performance using sports specific tasks remains to be 352 
determined.  353 
Importantly, the difference in TT time following a larger “dose”, 354 
through applying more (8x5-min) cycles in one session, was not 355 
deemed substantial enough, when compared to SHAM, to be of 356 
benefit. In addition, a smaller “dose” by applying unilateral IPC had 357 
little beneficial impact on performance. These results suggest for the 358 
first time, that IPC-mediated performance improvements are 359 
unlikely amplified by doubling the “traditional” number of IPC 360 
cycles. Nevertheless, it is unclear whether an area threshold is 361 
present for the “dose-tissue”. Whilst no negative impact on TT time 362 
was suggested from the magnitude based inference, the lack of 363 
additional benefit on exercise performance after the 8x5-min 364 
protocol provides support for the ‘hyperconditioning’ hypothesis, in 365 
that too many cycles may negate the beneficial effects of IPC 7. 366 
A recent animal model corroborated these findings and 367 
demonstrated four to six cycles yielded cardioprotection, with no 368 
further benefit after using eight cycles 28. Additionally, it was found 369 
that when using four cycles, both unilateral and bilateral hind-limb 370 
occlusion offered similar cardioprotection 28. The current study 371 
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findings suggest a bilateral “dose”, but not unilateral “dose”, may 372 
result in greater endurance performance; an outcome in line with one 373 
previous human study showing bilateral, but not unilateral IPC 374 
improved anaerobic sprint cycling performance 8. Whilst our data is 375 
specific to aerobic exercise performance, it may be possible that an 376 
“area threshold” i.e. a required amount tissue occlusion, is required 377 
to stimulate IPC-induced performance improvements, regardless of 378 
intensity 8,29. 379 
Remote IPC can elicit cardio protective effects, comparable to local 380 
IPC, possibly as a result of a humoral trigger signal or circulating 381 
factor 20. To date, the comparison between remote and local IPC has 382 
not been directly examined in an human performance setting, 383 
although both protocols have been previously reported to enhance 384 
performance when compared to SHAM 8,9. In our study, we provide 385 
the first direct evidence that local and remote application of IPC 386 
resulted in the same TT performance (288 watts, respectively). 387 
Whether a systemic pathway contribution towards improved 388 
exercise performance occurs, such as a humoral trigger signal or 389 
circulating factor similar to that shown with cardioprotection 20 390 
remains to be seen. Interestingly, clinical application of IPC locally 391 
or remotely is associated with a comparable protective effect against 392 
ischaemia-reperfusion injury in animals and humans 11. 393 
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TT performance after the traditional IPC “dose” was accompanied 394 
by a lower ?̇?O2 when compared to SHAM. Our data also reveal a 395 
lower TT ?̇?O2 for the same given workload (288w average) 396 
following local, compared to remote IPC. Whilst local IPC 397 
application can increase pig skeletal muscle metabolic efficiency 398 
under ischaemic conditions 2, it remains unknown whether 399 
previously observed local IPC-induced metabolic adaptations 9,30 400 
may have contributed to these findings. Nevertheless, the current 401 
data are suggestive that traditional IPC, applied locally, enhances 402 
the ability to sustain the same workload for a relatively lower 403 
oxygen cost compared to both SHAM and remote IPC, but this does 404 
not necessarily relate to clear improvements in power output. 405 
We recorded lactate measurements at each 25% stage of TT 406 
performance and found the traditional “dose” of IPC increased 407 
blood lactate during exercise when compared to both SHAM and the 408 
8x5-min condition. This finding is somewhat intriguing given that 409 
we have previously reported a lower onset of blood lactate 410 
accumulation (OBLA) during submaximal exercise following 4x5-411 
min (traditional) bilateral IPC compared to SHAM, hypothesizing 412 
greater lactate removal and transportation for uptake 9. A logical 413 
explanation for this apparent contrasting result is that workload in 414 
the current cycling TT task markedly exceeds that at OBLA. The 415 
increased blood lactate response in the current study following 4x5-416 
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min local bilateral IPC, combined with lower ?̇?O2, could be 417 
suggestive of alterations in substrate utilisation, with a proposed 418 
heightened anaerobic energy contribution. This was recently 419 
inferred by Cruz et al. 31, who demonstrated 4x5-min cycles of IPC 420 
improved 60-second sprint cycling performance and lead to an 421 
increased skeletal muscle activation during exercise, whilst during 422 
recovery produced higher amplitude of blood lactate kinetics and 423 
increased excess post-exercise oxygen consumption (EPOC), when 424 
compared to SHAM exercise. This, in combination with our data, 425 
suggests the potential ergogenic mechanisms relating to IPC-426 
induced metabolic alteration, is likely task and/or intensity specific. 427 
The capability of IPC to enhance aerobic exercise capacity 4,29,30, yet 428 
have smaller ergogenic effects on fixed-end-point performance 12 is 429 
a relationship also observed following the use of nitrate based 430 
dietary interventions 32 and might provide some insight into 431 
potential mechanisms. 432 
A systematic review and meta-analysis 12 recently reported IPC can 433 
enhance incremental exercise performance, time to exhaustion task 434 
performance, and fixed-end-point task performance by 2.4%, 5.8% 435 
and 0.5%, respectively. Additionally, Ferreira et al. 25 stated the 436 
estimated performance improvement of IPC was 1.5% based on 437 
some previous study findings 9,20,29. The current observed 438 
performance changes (1.4%) are broadly in line with the above 439 
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studies, yet the cycling mode we employed was a fixed-end-point 440 
task. We further delimited the impact of pacing strategy with 441 
rigorous familiarization trials (mean co-efficient of variation in TT 442 
time between trials was 1.1% ± 0.8%), and selecting only trained 443 
cyclists as participants. 444 
Practical Applications: 445 
IPC is a well-tolerated intervention for the competing individual 446 
(table 4). The magnitude of improvement after a bilateral 4x5-min 447 
protocol, independent of whether cuffs are placed locally (upper 448 
thighs) or remotely (upper arms), lead to improvements in finish 449 
time. This conclusion is based on the calculated typical error of our 450 
laboratory based test. Given the performance changes in laboratory 451 
based tests are different to the field and in competition (e.g. power-452 
velocity relationship on the road is cubic and not linear) this needs 453 
to be taken into account when applying these findings to road 454 
competition.  455 
Conclusion 456 
Our results suggest the “traditional” protocol of IPC involving 4x5-457 
min occlusion is associated with the fastest TT time compared to 458 
SHAM, in  a laboratory 375 kJ TT task, aimed to simulate demands 459 
of a 16.1 km road TT race. Moreover, by applying different IPC 460 
protocols in a within-subject cross-over design, our data suggests no 461 
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benefit when increasing the “dose” by doubling the number of 462 
cycles or reducing the “dose” via implementing unilateral IPC. 463 
Finally, TT performance after IPC appears to be independent of the 464 
localization of the cuffs, as IPC applied to the upper limbs resulted 465 
in the same TT time. 466 
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 628 
Figure 1 – Schematic of different of IPC protocols (i) comparison of 629 
dose-cycles (ii) comparison of dose-tissue and (ii) comparison 630 
remote. (N.B. traditional dose of IPC was performed once in the 631 
experimental design but is shown 3 times on schematic to highlight 632 
the comparisons). 633 
 634 
 635 
 636 
 637 
 638 
 639 
 640 
 641 
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 642 
 643 
Figure 2a – Overall TT times (with individual times plotted) for IPC 644 
(i) comparison of dose-cycles (ii) comparison of dose-tissue (iii) 645 
comparison of remote. 646 
Figure 2b – A between-condition representation of the likelihood of 647 
“beneficial”, “trivial”, or “harmful” performance outcome to 648 
endurance cycling TT performance. 649 
28 
 
Tables: 650 
Table 1: The effect of “dose-cycles” on power, heart rate, rate of 651 
perceived exertion and ?̇?O2 following 25%, 50%, 75% and 100% 652 
time points during time trial performance. 653 
  Intervention   P values 
  Average 0-25% 25-50% 50-75% 75-100%       
Power 
(watts)                 
4x5 288 ± 33 310 ± 38 284 ± 34 275 ± 34 285 ± 32   Condition 0.57 
8x5 286 ± 35 307 ± 37 284 ± 35 273 ± 37 281 ± 36   Time < 0.005 
SHAM 285 ± 35 305 ± 38 282 ± 39 273 ± 35 284 ± 35   Condition x time 0.99 
           
Lactate 
(mmol.L-1)          
4x5 11.8 ± 2.8 10.8 ± 3.4 11.8 ± 3.2 12.4 ± 2.9 13.4 ± 2.8*   Condition 0.02* 
8x5 11.2 ± 3.1 10.6 ± 3.7 11.2 ± 3.2 11.3 ± 3.3 11.6 ± 3.2*   Time < 0.005 
SHAM 11.4 ± 4.3 10.1 ± 4 10.7 ± 5.1 11.5 ± 4.5 13.2 ± 4.4   Condition x time 0.69 
           
HR (BPM)          
4x5 168 ± 11 158 ± 12 168 ± 11 170 ± 10 173 ± 10   Condition 0.45 
8x5 167 ± 13 158 ± 15 166 ± 13 170 ± 13 173 ± 13   Time < 0.005 
SHAM 166 ± 14 154 ± 15 165 ± 14 168 ± 14 171 ± 14   Condition x time 0.96 
           
RPE (Borg 
scale  
6-21)          
4x5 17.7 ± 1.1 16.1 ± 1.6 17.2 ± 1.5 17.7 ± 1.3 19.3 ± 0.9   Condition 0.83 
8x5 17.7 ± 1.1 16.6 ± 1.1 17.3 ± 1.3 17.9 ± 1.2 18.8 ± 1.1   Time < 0.005 
SHAM 17.6 ± 1 16.2 ± 1.3 17.1 ± 1.2 17.8 ± 1.4 19 ± 0.9   Condition x time 0.64 
           
V ̇O2 
(ml.kg.min-1)          
4x5 52.6 ± 4.4 49.8 ± 3.3 54.6 ± 4.8 53.2 ± 5.3 52.8 ± 4.7   Condition 0.08 
8x5 52.8 ± 4.3 50.3 ± 3.6 54.8 ± 4.7 53.6 ± 5.3 52.8 ± 4.7   Time < 0.005 
SHAM 53.3 ± 4.4 50.4 ± 3.7 55.6 ± 4.7 54.1 ± 4.8 53.3 ± 4.9   Condition x time 0.1 
                  
         
 654 
 655 
 656 
 657 
 658 
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Table 2: The effect of “dose-tissue” on power, heart rate, rate of 659 
perceived exertion and ?̇?O2 following 25%, 50%, 75% and 100% 660 
time points during time trial performance. 661 
 662 
  Intervention   P values   
  Average 0-25% 25-50% 50-75% 75-100%         
Power 
(Watts)                   
BILATERAL 288 ± 33 310 ± 38 284 ± 34 275 ± 34 285 ± 32   Condition  0.43 
UNI 285 ± 38 305 ± 45 282 ± 42 275 ± 36 282 ± 36   Time  < 0.005 
         Condition x time 0.75 
          
Lactate 
(mmol.L-1)              
BILATERAL 11.8 ± 2.8 10.7 ± 3.4 11.5 ± 3.2 12 ± 2.7 13.1 ± 2.9   Condition  0.83 
UNI 11.7 ± 3.5 10.9 ± 3.9 11.6 ± 4.1 11.8 ± 3.6 12.9 ± 3.7   Time  0.001 
         Condition x time 0.1 
             
HR (BPM)            
BILATERAL 168 ± 11 158 ± 12 168 ± 11 170 ± 10 173 ± 10   Condition  0.21 
UNI 168 ± 13 158 ± 15 169 ± 13 171 ± 14 173 ± 13   Time  < 0.005 
         Condition x time 0.38 
             
RPE (Borg 
scale 6-21)            
BILATERAL 17.7 ± 1.1 16.1 ± 1.6 17.2 ± 1.5 17.7 ± 1.3 19.3 ± 0.9   Condition  0.44 
UNI 17.5 ± 1 16.3 ± 1.2 17.3 ± 1 17.7 ± 1.2 18.9 ± 1   Time  < 0.005 
         Condition x time 0.77 
             
V ̇O2 
(ml.kg.min-1)            
BILATERAL 52.6 ± 4.2 49.8 ± 3.4 54.6 ± 4.5 53.2 ± 5 52.8 ± 4.6   Condition  0.26 
UNI 52.5 ± 5.6 49 ± 4.5 54 ± 6.2 53.8 ± 6.1 53.3 ± 6   Time  < 0.005 
         Condition x time 0.06 
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 670 
Table 3: The effect of “remote” IPC on power, heart rate, rate of 671 
perceived exertion and ?̇?O2 at 25%, 50%, 75% and 100% time 672 
points during time trial performance. 673 
 674 
  Intervention   P values   
  Average 0-25% 25-50% 50-75% 75-100%         
Power 
(Watts)                   
LOCAL 288 ± 33 310 ± 38 284 ± 34 275 ± 34 285 ± 32   Condition  0.8 
REMOTE 288 ± 35 308 ± 39 286 ± 33 277 ± 35 286 ± 40   Time  < 0.005 
         Condition x time 0.94 
          
Lactate 
(mmol.L-1)              
LOCAL 11.8 ± 3 10.7 ± 3.4 11.5 ± 3.2 12 ± 2.7 13.1 ± 3   Condition  0.24 
REMOTE 11.4 ± 5 9.8 ± 3.9 11.2 ± 4 11.4 ± 4 13.4 ± 6.1   Time  < 0.005 
         Condition x time 0.93 
             
HR (BPM)            
LOCAL 168 ± 11 158 ± 12 168 ± 11 170 ± 10 173 ± 10   Condition  0.56 
REMOTE 167 ± 14 158 ± 15 168 ± 14 171 ± 13 173 ± 13   Time  < 0.005 
         Condition x time 0.41 
             
RPE (Borg 
scale 6-21)            
LOCAL 17.7 ± 1.1 16.1 ± 1.6 17.2 ± 1.5 17.7 ± 1.3 19.3 ± 0.9   Condition  0.72 
REMOTE 17.6 ± 1.1 16.5 ± 1.2 17.3 ± 1.4 17.6 ± 1.2 19 ± 1   Time  < 0.005 
         Condition x time 0.57 
             
V ̇O2 
(ml.kg.min-1)            
LOCAL 
52.6 ± 3.8 49.8 ± 3.1 54.6 ± 4.1 53.2 ± 4.6* 52.8 ± 4.4 
  Condition  0.04* 
REMOTE 
53.4 ± 4.3 50.4 ± 3.3 55.1 ± 4.6 54.5 ± 5* 53.7 ± 5 
  Time  < 0.005 
         Condition x time 0.36 
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 682 
 683 
Table 4: Perceived discomfort of IPC and SHAM interventions. 684 
  Perceived discomfort of condition (ratings 0-10)   
Mean discomfort 
rating 
  Average 0-10 min 10-20 min 20-30 min 30-40 min     
         
Traditional 4x5 
IPC (legs) 3.7  ± 1.2 4.5 ± 1.5 3.5 ± 1.1 3.5 ± 1.1 3.4 ± 1.1   Light to moderate 
                
Larger 8x5 cycles 3.6 ± 1.7 3.9 ± 1.8 3.5 ± 1.6 3.3 ± 1.8 3.5 ± 1.8   Light to moderate 
                
Unilateral 4x5 
IPC 
3.1 ± 1.5 3.5 ± 1.9 3.1 ± 1.5 2.8 ± 1.3 2.8 ± 1.5   Light to moderate 
                
Remote 4x5 IPC 
(arms) 
3.7 ± 2.1 4.1 ± 2 3.6 ± 2 3.7 ± 2 3.4 ± 2.3   Light to moderate 
                
SHAM 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0   No discomfort 
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